scfv和vhh都是基因工程化细胞药物非常好的选择，无论是car-t还是car-nk等细胞治疗，其中最核心的与靶细胞结合的car都是由scfv或者vhh构成。而且，vhh由于分子量小、易于人源化、理化性质稳定，越来越多的细胞治疗使用vhh。 三、结论与展望

2023年5月24日 · 尺寸在纳米范围内的重组抗原特异性单结构域VHH也称为纳米抗体（Nb）或单结构域抗体（sdAb）。 在这篇综述中，我们总结了HCAbs和VHH结构域的主要结构特征，并提供了骆驼科中HCAbs可能产生机制的更新。

纳米抗体（nanobody, Nb）是一种人工设计的抗体分子，又称为单域抗体（single-domain antibodies, sdAbs）、VHH抗体或camelid抗体，是发现于羊驼、单峰驼等驼科以及鲨鱼、鳐鱼等软骨鱼中的一种天然缺失轻链的重链抗体（heavy-chain antibodies, HCAbs)。 1993年，比利时的科学家在骆驼的血清中发现了一种天然轻链缺失的重链抗体，分子量约95 kDa，其中包括两个恒定区（CH2和CH3）、一个铰链区和一个重链可变区（variable heavy chain domain, VHH），接 …

2020年9月11日 · 骆驼体内存在天然的缺失轻链的重链抗体，克隆其可变区可以得到只有重链可变区组成的单域抗体，称为VHH(Variable domain of heavy chain of heavy chain antibody)，也称为纳米抗体(nanobody, a single domain antibody)，它是最小的功能性抗原结合片段。

A VHH antibody (or nanobody) is the antigen binding fragment of heavy chain only antibodies. Discovered nearly 25 years ago, they have been investigated for their use in clinical therapeutics and immunodiagnostics, and more recently for ...

2023年8月19日 · We show that the CDR-H3 conformation of VHHs correlates with the germline from which the antibodies are derived: IGHV3-3 derived antibodies almost exclusively adopt a kinked CDR-H3 conformation...

VHH, i.e., VH domains of camelid single-chain antibodies, are very promising therapeutic agents due to their significant physicochemical advantages compared to classical mammalian antibodies. The number of experimentally solved VHH structures has ...

2020年8月11日 · VHH antibodies are the isolated VHH domains of heavy-chain only IgG2 and IgG3 antibodies produced by camelid species, such as alpaca, llama, and camel. These proteins consist of framework regions and three highly variable loops; H1, H2 and H3.

2022年3月28日 · V H H, i.e., VH domains of camelid single-chain antibodies, are very promising therapeutic agents due to their significant physicochemical advantages compared to classical mammalian antibodies. The number of experimentally solved V H H structures has significantly improved recently …

2022年3月28日 · VHH, i.e., VH domains of camelid single-chain antibodies, are very promising therapeutic agents due to their significant physicochemical advantages compared to classical mammalian antibodies.